Literature DB >> 18572163

Disruption of the complement cascade delays retinal ganglion cell death following retinal ischemia-reperfusion.

Markus H Kuehn1, Chan Y Kim, Bing Jiang, Alina V Dumitrescu, Young H Kwon.   

Abstract

Recent reports have indicated that components of the complement cascade are synthesized during the degeneration of retinal ganglion cells (RGC) in glaucoma. While complement deposition in the retina may simply serve to aid phagocytosis of damaged RGC, activation of the complement cascade can also contribute to neuronal loss in neurodegenerative diseases. This study was designed to determine if disruption of the complement cascade affects RGC survival in a murine model of retinal ischemia-reperfusion (I/R) injury. We induced retinal ischemia in the eyes of normal mice and mice with a targeted disruption of the complement component 3 (C3) gene. Tissue was harvested 7 and 21 days after induction of I/R and retinal complement synthesis was determined by quantitative PCR and immunohistochemical methods. RGC death and associated axon loss was evaluated through histological examination of the optic nerve and retina. Our data show that retinal I/R induces the expression and deposition of complement components. C3 deficient mice clearly exhibited reduced optic nerve damage and substantial preservation of RGC 1 week after I/R when compared to normal animals (p=0.005). Three weeks after the ischemic event C3 deficient mice retained more RGC cell bodies although the degree of optic nerve damage was similar between both groups. These findings demonstrate that inhibition of the complement cascade delays optic nerve axonal and RGC degeneration in retinal I/R. It appears that injured RGC are targeted and actively destroyed through complement mediated processes. These results may have implications for the pathophysiology and clinical management of ischemic retinal conditions.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18572163     DOI: 10.1016/j.exer.2008.04.012

Source DB:  PubMed          Journal:  Exp Eye Res        ISSN: 0014-4835            Impact factor:   3.467


  33 in total

1.  Transplantation of BDNF-secreting mesenchymal stem cells provides neuroprotection in chronically hypertensive rat eyes.

Authors:  Matthew M Harper; Sinisa D Grozdanic; Bas Blits; Markus H Kuehn; Daniel Zamzow; Janice E Buss; Randy H Kardon; Donald S Sakaguchi
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-06-23       Impact factor: 4.799

2.  Complement C3-Targeted Gene Therapy Restricts Onset and Progression of Neurodegeneration in Chronic Mouse Glaucoma.

Authors:  Alejandra Bosco; Sarah R Anderson; Kevin T Breen; Cesar O Romero; Michael R Steele; Vince A Chiodo; Sanford L Boye; William W Hauswirth; Stephen Tomlinson; Monica L Vetter
Journal:  Mol Ther       Date:  2018-08-24       Impact factor: 11.454

3.  Transplantation of iPSC-derived TM cells rescues glaucoma phenotypes in vivo.

Authors:  Wei Zhu; Oliver W Gramlich; Lauren Laboissonniere; Ankur Jain; Val C Sheffield; Jeffrey M Trimarchi; Budd A Tucker; Markus H Kuehn
Journal:  Proc Natl Acad Sci U S A       Date:  2016-06-06       Impact factor: 11.205

Review 4.  Differential gene expression in glaucoma.

Authors:  Tatjana C Jakobs
Journal:  Cold Spring Harb Perspect Med       Date:  2014-07-01       Impact factor: 6.915

5.  Lack of immunoglobulins does not prevent C1q binding to RGC and does not alter the progression of experimental glaucoma.

Authors:  Qiong J Ding; Amy C Cook; Alina V Dumitrescu; Markus H Kuehn
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-09-19       Impact factor: 4.799

6.  Oxidative stress and the regulation of complement activation in human glaucoma.

Authors:  Gülgün Tezel; Xiangjun Yang; Cheng Luo; Angela D Kain; David W Powell; Markus H Kuehn; Henry J Kaplan
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-05-19       Impact factor: 4.799

7.  Genetic Deficiency of Complement Component 3 Does Not Alter Disease Progression in a Mouse Model of Huntington's Disease.

Authors:  Paul B Larkin; Paul J Muchowski
Journal:  J Huntingtons Dis       Date:  2012

Review 8.  [Basic biochemical processes in glaucoma progression].

Authors:  N von Thun und Hohenstein-Blaul; S Kunst; N Pfeiffer; F H Grus
Journal:  Ophthalmologe       Date:  2015-05       Impact factor: 1.059

9.  Localization of complement 1 inhibitor (C1INH/SERPING1) in human eyes with age-related macular degeneration.

Authors:  Robert F Mullins; Elizabeth A Faidley; Heather T Daggett; Catherine Jomary; Andrew J Lotery; Edwin M Stone
Journal:  Exp Eye Res       Date:  2009-07-14       Impact factor: 3.467

Review 10.  The complex role of neuroinflammation in glaucoma.

Authors:  Ileana Soto; Gareth R Howell
Journal:  Cold Spring Harb Perspect Med       Date:  2014-07-03       Impact factor: 6.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.